Biogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively
January 25, 2018 6:29 AM EST2017 total revenues grew 7% or 15% excluding hemophilia revenues*
2017 GAAP EPS decreased 30%, including a $1.2 billion charge due to U.S. tax reform
2017 non-GAAP EPS grew 8%
Company added seven clinical programs to neuroscience pipeline in 2017
Company provides 2018 full year revenue guidance of $12.7 to $13.0 billion
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (Nasdaq: BIIB) today reported full year and fourth quarter 2017 financial results, including:
Full year total revenues of $12.3 billion, a 7% increase versus the prior year or a 15% increase... More